New CAR T-Cell therapy takes on Hard-to-Treat cancers
NCT ID NCT07216105
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are to check safety and find the best dose when given alone or with chemotherapy and/or antibody drugs. About 113 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
-
University of Minnesota Masonic Cancer Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
University of Southern California
RECRUITINGLa Jolla, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts